{"id":402304,"date":"2023-12-28T02:37:32","date_gmt":"2023-12-28T07:37:32","guid":{"rendered":"https:\/\/platohealth.ai\/astrazeneca-buys-chinese-gracell-biotechnologies-for-1-2bn\/"},"modified":"2023-12-28T04:45:02","modified_gmt":"2023-12-28T09:45:02","slug":"astrazeneca-buys-chinese-gracell-biotechnologies-for-1-2bn","status":"publish","type":"post","link":"https:\/\/platohealth.ai\/astrazeneca-buys-chinese-gracell-biotechnologies-for-1-2bn\/","title":{"rendered":"AstraZeneca buys Chinese Gracell Biotechnologies for $1.2bn","gt_translate_keys":[{"key":"rendered","format":"text"}]},"content":{"rendered":"
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn.<\/p>\n<\/p><\/div>\n
Pharmaceutical giant Astrazeneca with CEO Pascal Soriot wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects. This was announced by the Swedish-British group on Tuesday. A total of around 1.2 billion US dollars has been earmarked for the purchase.<\/p>\n
Gracell Biotechnologies develops cell therapies for the treatment of cancer and autoimmune diseases. The company is to operate in future as a wholly owned subsidiary of Astrazeneca with branches in China and the USA. According to a statement from Astrazeneca the acquisition is expected to close in the first quarter of 2024, subject to customary closing conditions, including regulatory approvals, and Gracell shareholder approval.\n<\/p>\n
The Chinese biotech’s pipeline is led by GC012F, a BCMA and CD19 dual-targeting autologous CAR-T that is in a phase 1b\/2 trial in relapsed refractory multiple myeloma in the US and a trial in China, including refractory systemic lupus erythematosus. GC012F was developed using the company’s FasTCAR platform, which is designed to reduce manufacturing time and enhance T-cell fitness to improve treatment efficacy in patients.<\/p>\n<\/p><\/div>\n
Pharmaceutical giant AstrazZeneca wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects in a deal worth up to $1.2bn. Pharmaceutical giant Astrazeneca with CEO Pascal Soriot wants to take over the Chinese company Gracell Biotechnologies in order to strengthen its cell therapy projects. This was announced by […]<\/p>\n","protected":false,"gt_translate_keys":[{"key":"rendered","format":"html"}]},"author":2,"featured_media":402307,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[50],"tags":[],"acf":[],"gt_translate_keys":[{"key":"link","format":"url"}],"_links":{"self":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/402304"}],"collection":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/comments?post=402304"}],"version-history":[{"count":1,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/402304\/revisions"}],"predecessor-version":[{"id":402306,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/posts\/402304\/revisions\/402306"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media\/402307"}],"wp:attachment":[{"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/media?parent=402304"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/categories?post=402304"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/platohealth.ai\/wp-json\/wp\/v2\/tags?post=402304"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}